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ABSTRACT: The enzyme N-myristoyltransferase (NMT)
catalyzes the essential fatty acylation of substrate proteins
with myristic acid in eukaryotes and is a validated drug target
in the parasite Trypanosoma brucei, the causative agent of
African trypanosomiasis (sleeping sickness). N-Myristoylation
typically mediates membrane localization of proteins and is
essential to the function of many. However, only a handful of
proteins are experimentally validated as N-myristoylated in T.
brucei. Here, we perform metabolic labeling with an alkyne-
tagged myristic acid analogue, enabling the capture of lipidated
proteins in insect and host life stages of T. brucei. We further
compare this with a longer chain palmitate analogue to explore
the chain length-speciﬁc incorporation of fatty acids into proteins. Finally, we combine the alkynyl-myristate analogue with NMT
inhibitors and quantitative chemical proteomics to globally deﬁne N-myristoylated proteins in the clinically relevant bloodstream
form parasites. This analysis reveals ﬁve ARF family small GTPases, calpain-like proteins, phosphatases, and many
uncharacterized proteins as substrates of NMT in the parasite, providing a global view of the scope of this important protein
modiﬁcation and further evidence for the crucial and pleiotropic role of NMT in the cell.
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Human African trypanosomiasis (HAT), or Africansleeping sickness, is a usually fatal tropical disease caused
by unicellular eukaryotic parasites of the species Trypanosoma
brucei and transmitted by an insect vector. Although the
number of reported cases has dropped in recent years,1 an
estimated 21 million people are at high to moderate risk of the
disease.2 In addition, the analogous livestock disease, Nagana,
causes an estimated 3 million cattle deaths per year with
signiﬁcant economic impact.3 T. brucei gambiense, responsible
for >98% of HAT cases, causes a chronic infection in which the
early stage, lasting several months or years, is relatively
asymptomatic; later in infection, parasites cross the blood−
brain barrier and invade the central nervous system, ultimately
leading to coma and death. There are few treatments currently
available to treat late-stage HAT, and all suﬀer from high
toxicity, high expense, or problematic delivery.4 T. brucei is
transmitted primarily by the bite of an infected tsetse ﬂy, which
injects the metacyclic trypomastigote form of the parasite into
the mammalian host, although mother to fetus transmission can
also occur. The parasite then transforms into the bloodstream
form (BSF), which remains extracellular in the bloodstream and
lymph. When a tsetse ﬂy takes a blood meal from an infected
host, parasites are taken up and transform into procyclic forms
(PCFs) that multiply in the insect gut prior to transformation
into epimastigotes, which travel to the insect salivary gland.5
The BSF is therefore of most interest for treatment of infection
and progression of the disease, whereas the PCF is important
for replication in the insect vector. The adaptive diﬀerences
between BSF and PCF, and the process of diﬀerentiation, are
important for druggability of BSF trypanosomes in the
mammalian host.
The enzyme myristoyl-CoA:protein N-myristoyltransferase
(NMT) is an essential eukaryotic enzyme that catalyzes
attachment of the C14:0 fatty acid myristate from myristoyl-
CoA to the N-terminal glycine residue of a subset of cellular
proteins.6 N-Myristoylation mediates membrane localization,
modulates stability, or regulates protein−protein interactions,
and NMT has been investigated as a potential drug target in
HAT,7 fungal infections,8 leishmaniases,9 malaria,10 nemat-
odes,11 and cancer.12 Structure-based design and high-
throughput screening have yielded multiple NMT inhibitor
series, some with species selectivity.7,13 In T. brucei, RNAi
knockdown of NMT results in abnormal morphology and
defects in endocytic traﬃcking.14 Traﬃcking defects may in
part be related to loss of myristoylation of members of the
ADP-ribosylation factor (ARF) family of small GTPases
involved in vesicular traﬃcking in eukaryotes. RNAi depletion
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of two N-myristoylated T. brucei ARFs showed that the proteins
are essential for viability of BSF parasites and revealed defects
in subcellular structures such as the ﬂagellar pocket (the site of
almost all endo- and exocytosis), vesicles, and the Golgi
apparatus.15 In 2010, Frearson et al. reported a series of NMT
inhibitors with high potency against the T. brucei enzyme, with
the ability to cure trypanosomiasis in mice.7,13a,b The
phenotype of inhibitor treatment was distinct from RNAi
knockdown of NMT, but the parasite did exhibit an enlarged
ﬂagellar pocket.7 Given the cotranslational nature of N-
myristoylation, NMT inhibitors would be expected to aﬀect
viability of both BSF and PCF parasites, because both forms
replicate; in terms of clinical treatment, however, targeting BSF
parasites is of most interest.
Bioinformatic analyses suggest that more than 60 proteins
may be N-myristoylated in T. brucei, resulting in the prediction
that NMT inhibition will have pleiotropic eﬀects on the
parasite.16 There is some experimental evidence for N-
myristoylation of a few parasite proteins: three ARFs,15a,b,17
cytoskeleton-associated protein CAP5.5,18 Calﬂagin,19 phos-
phatase PPEF,16 ﬂagellar-calcium binding protein FCaBP (in
the related parasite T. cruzi),20 and virulence-associated
metacaspase 4 (MCA4).21 However, global characterization of
N-myristoylation by standard biochemical methods such as
radiolabeling is hampered by low sensitivity, the need for
speciﬁc antibodies for target proteins, and the frequent
requirement for artiﬁcial overexpression to achieve detection.
We and others have recently made use of the metabolic
incorporation of bioorthogonally tagged fatty acids to globally
proﬁle myristoylation and other protein lipidations in diverse
organisms,22 including the trypanosomatid parasite Leishmania
donovani, which causes leishmaniasis.23 Here we apply this
technology to study lipidation in T. brucei, comparing acylated
proteins in the insect (PCF) and host (BSF) life stages using a
tagged analogue of myristate and analyzing acylation patterns
with a tagged palmitate analogue. Finally, we quantify changes
in acylation levels in the presence of NMT inhibitors and
demonstrate selective target engagement across the proteome
through quantitative chemical proteomic analyses. Taken
together, these data globally deﬁne NMT substrates in the
key life stages of the parasite and provide insight into the
mechanism of action of NMT inhibitors in T. brucei.
■ RESULTS AND DISCUSSION
Fatty acids bearing terminal alkyne or azide modiﬁcations are
known to be tolerated by the cellular machinery in diverse
systems and incorporated into acylated proteins.22a Our
approach uses myristic acid analogue YnMyr (Figure 1a), the
coenzyme-A analogue of which is accepted as a substrate by
NMTs and which we have previously shown is incorporated
into N-myristoylated proteins in Plasmodium falciparum,10
Leishmania donovani,23 human cancer cells,12 virus-infected
Figure 1. YnMyr labels proteins in T. brucei PCF parasites. (a) Overview of tagging strategy. YnMyr or myristic acid (Myr) was added to T. brucei
parasite cultures and incorporated metabolically into lipidated proteins. The alkyne tag was reacted by CuAAC with ﬂuorophore and/or biotin-
functionalized azide capture reagents (Supporting Information Figure S1) to allow downstream enrichment and analysis by proteomics and SDS-
PAGE. (b) Labeling with YnMyr or Myr (−) in PCF parasites. After 18 h of incubation with probes at 100 μM, parasites were lysed, and proteins
were reacted with AzTB and separated by gel for ﬂuorescence scanning. Samples were treated with NaOH or precipitated with chloroform/methanol
(C/M) as indicated. (c) Speciﬁc PCF labeling is resistant to treatment with Pronase. Coomassie gels are shown in Supporting Information Figure S2.
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cells,24 and zebraﬁsh embryos.25 After cell lysis, alkyne-tagged
proteins are captured by a click reaction, the copper-catalyzed
cycloaddition of an alkyne and azide (CuAAC), appending a
variety of groups such as a ﬂuorophore for visualization and/or
biotin for aﬃnity pull-down.26 Enriched proteins are then
subject to tryptic digest and shotgun LC-MS/MS analysis for
proteomic identiﬁcation (Figure 1a).
YnMyr Labels Proteins in T. brucei. To investigate
whether YnMyr can be used to label proteins in T. brucei,
cultures of PCF parasites were incubated for 18 h with 100 μM
YnMyr or myristic acid (Myr) control. Following cell lysis,
tagged proteins were ligated to biotin and TAMRA function-
alized reagent AzTB (Supporting Information Figure S1) via
CuAAC and visualized by in-gel ﬂuorescence following
separation by SDS-PAGE. In addition to multiple discrete
bands, two diﬀuse bands were observed between 20 and 40 kDa
(Figure 1b), which could be removed by chloroform−methanol
precipitation or base treatment of proteins after CuAAC.
Trypanosomatid parasites are abundant in complex glycolipids,
and PCF T. brucei possesses a family of surface proteins, the
procyclins, which bear a glycan-elaborated glycosylphosphati-
dylinositol (GPI)-anchor near their C-terminus and in some
cases N-glycosylation in the N-terminal domain.27 When
separated by SDS-PAGE, procyclins migrate as two poly-
disperse bands at ∼30 and 40 kDa and can be radiolabeled with
[3H]-myristate.28 Treatment of YnMyr-labeled PCF samples
with Pronase shifted a proportion of the diﬀuse bands to lower
molecular weight and completely removed the majority of
labeling (Figure 1c), consistent with the discrete bands
corresponding to proteins and the diﬀuse bands corresponding
to the partially protease-resistant procyclins. Alternatively, the
diﬀuse bands may correspond to other glycolipid components,
such as free poly-N-glycosylated GPIs that are also present on
the surface of T. brucei PCF.28a
Having established that YnMyr could label proteins in the
procyclic insect stage form of T. brucei, we focused on host
stage parasites. Cultured BSF cells were incubated with 100 μM
YnMyr or Myr for 4, 8, or 18 h and lysates processed as
described above. Labeling intensity increased from 4 to 8 h but
decreased again at 18 h, at which time point YnMyr-related
toxicity was also observed (Figure 2a,b; Supporting Information
Figure S3); parasites exhibited the so-called “Big Eye”
phenotype, which is characterized by an enlarged ﬂagellar
pocket. This phenotype is the result of a block in receptor-
mediated endocytosis and has previously been described
following RNAi knockdown of clathrin heavy chain29 and the
small GTPase ARF1.15b Consistent with our results, YnMyr was
previously shown to be moderately toxic to T. brucei in a study
seeking to identify inhibitors of variant surface glycoprotein
(VSG) GPI myristoylation.30 The VSG coats the surface of BSF
T. brucei and is unusual in incorporating speciﬁcally diacyl-
myristate into its GPI anchor.31 This feature is unique to T.
brucei BSF, and multiple cellular pathways have evolved to
ensure that myristate alone is incorporated. We hypothesize
that the observed YnMyr toxicity is related to disruption of the
VSG myristate pathway, and an 8 h tagging step was therefore
used in subsequent experiments to circumvent YnMyr-related
toxicity and focus analysis on N-myristoylated proteins.
Figure 2. YnMyr labels proteins in T. brucei BSF parasites. (a) Time-dependent metabolic incorporation of 100 μM YnMyr or Myr (−) in BSF
parasites. (b) Phenotype of YnMyr treatment at 18 h in BSF. Scale bar = 10 μm. See also Supporting Information Figure S3. (b) NaOH treatment of
lysates from BSF parasites incubated with YnMyr reveal labeling of a base sensitive band at ∼60 kDa. (d) Chemical structures of myristate analogues
YnMyr and AzMyr and palmitate analogue YnPal. (e) Comparative labeling with diﬀerent fatty acid analogues at 100 μM in BSF. Coomassie gels are
shown in Supporting Information Figure S2. Additional data are shown in Supporting Information Figure S4.
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A prominent band between 50 and 75 kDa showed
sensitivity to treatment with strong base (NaOH; Figure 2c;
Supporting Information Figure S4), indicating ester-linked
YnMyr and consistent with incorporation of the probe into the
GPI anchor of the VSG, as expected. We have previously
observed signiﬁcant incorporation of tagged fatty acids into
GPI-anchored proteins in the malaria parasite P. falciparum.10
The majority of other bands were insensitive to base treatment,
implying amide-linked YnMyr. Azido-myristate mimetic AzMyr
gave very similar labeling to YnMyr, as expected, whereas
longer chain palmitate analogue YnPal gave a distinct pattern
(Figure 2d,e). These data are consistent with incorporation of
tagged fatty acids into proteins by chain-length speciﬁc
acyltransferases such as NMT and palmitoylacyltransferases
(PATs).
Proteomic Identiﬁcation of YnMyr-Labeled Proteins
in T. brucei. We have previously shown that YnMyr is
incorporated into putative N-myristoylated protein ARL6 via
labeling of this protein after immunoprecipitation (IP).17
However, the IP method relies on the availability of an
antibody to the protein of interest and has very low throughput.
To carry out global identiﬁcation of the proteins labeled in BSF
and PCF parasites, tagged proteins were ligated to AzTB and
enriched by pull-down onto NeutrAvidin-coated resin through
the biotin aﬃnity label (Supporting Information Figure S5).
Bead-bound proteins were subject to tryptic digest and peptides
analyzed by LC-MS/MS. Each sample set consisted of a YnMyr
sample and Myr control, prepared in parallel. Raw data were
searched using MaxQuant32 and a database of the T. brucei
TREU 927 reference strain (TriTrypDB33). In-gel ﬂuorescence
analysis suggested that the VSG was also labeled with YnMyr.
Since the VSG variant is strain-speciﬁc, initial BSF experimental
data were therefore also searched against the T. brucei Lister
strain 427, identifying VSG variant Tb427.BES40.22; this
protein sequence was appended to the TREU 927 FASTA ﬁle
for all subsequent searches. Data were analyzed using label-free
quantiﬁcation (LFQ), a technique that normalizes intensity
measurements to enable comparison between diﬀerent LC-
MS/MS runs, in MaxQuant (“MaxLFQ”).34 After Log2
transformation of intensities, data were ﬁltered to retain only
proteins present in several replicates, missing values were
imputed from a normal distribution to mimic values at the limit
of detection, and permutation-corrected two-sample t tests
were used to assess proteins signiﬁcantly enriched in YnMyr
samples over Myr controls (see Methods). A caveat to this
analytical workﬂow is that proteins detected in multiple YnMyr
samples but with low intensity will be assigned as nonsigniﬁcant
even if they are absent from Myr controls because their
intensity is too close to background; many of these proteins
could be genuine hits but of low abundance.
In BSF experiments, proteins were ﬁltered to retain only
those present in at least three of four replicates and in biological
duplicate, resulting in 101 signiﬁcantly enriched proteins in
YnMyr samples (Figure 3a; Supporting Information Table S1).
Of these, 46 (46%) are likely to carry an N-terminal glycine
implied by an MG motif at the N-terminus, which is thought to
be a requirement for NMT-dependent myristoylation.35 In
PCF experiments, proteins were ﬁltered to retain only those
present in at least four of the six technical replicates and in
biological duplicate, identifying 91 proteins as signiﬁcantly
enriched in YnMyr samples (Figure 3b; Supporting Informa-
tion Table S2); again, roughly half of these proteins have an N-
terminal MG motif.
Non-MG proteins highly enriched in YnMyr samples include
glycosylphosphatidylinositol-speciﬁc phospholipase C (GPI-
PLC), a protein that is S-myristoylated,36 in BSF samples,
and MSP-B (a homologue of GPI-anchored Leishmania GP63
surface protease), procyclic form surface phosphoprotein
(PSSA-2), and p-glycoprotein-A in PCF parasites. The GPI-
anchored VSG was also detected in BSF samples and was
enriched in YnMyr experiments compared to controls. Proteins
previously shown to be N-myristoylated in T. brucei or related
species included ﬂagellar calcium binding protein (FCaBP,
shown to be N-myristoylated in T. cruzi),20 cytoskeleton-
associated protein CAP5.5,18 the proteasome regulatory
ATPase subunit 2 (RPT2), which is known to be N-
myristoylated in many eukaryotes,37 a phosphatase of the
Figure 3. Identiﬁcation of YnMyr-tagged proteins in (a) BSF and (b)
PCF T. brucei. Volcano plots show signiﬁcance of enrichment over
background. Parasites were treated with Myr or YnMyr, lysates labeled
by CuAAC, and proteins enriched by biotin−streptavidin interaction
and digested by trypsin for LC-MS/MS. Proteins from four (BSF) or
six (PCF) replicates (independent sample processing from the lysate
stage; includes a biological replicate in each case) were quantiﬁed by
label-free quantiﬁcation (MaxLFQ). After ﬁltering to retain only those
proteins present in biological duplicate and in 3 of 4 (BSF) or 4 of 6
(PCF) samples, missing intensities were imputed from a normal
distribution chosen to mimic noise level, and a modiﬁed t test with
permutation-based FDR statistics was applied (250 permutations) to
compare Myr and YnMyr groups. BSF and PCF: FDR = 0.001; s0 = 1.
Proteins containing an N-terminal glycine (MG) and those for which
the YnMyr-modiﬁed peptide was identiﬁed using reagents AzRB or
AzRTB in the respective lifestage are indicated. ARF* indicates
multiple proteins in this proteinGroup. See also Supporting
Information Tables S1−S3.
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PPEF family,16 and a GRASP homologue (acylated in other
protozoan parasites38). Metacaspase 4 (MCA4), previously
shown to be palmitoylated at a cysteine residue proximal to a
likely N-myristoylation site, was also identiﬁed, principally in
BSF samples; this pseudopeptidase is an important virulence
factor in T. brucei infection.21 Several ARF/ARLs, a well-studied
family of N-myristoylated small GTPases, were also identiﬁed
across the data sets: these included Tb927.7.6230, now called
ARF3 (GeneDB) but previously known as ARL1, and shown to
be both N-myristoylated and essential to survival of BSF T.
brucei.15a,c ARL6 (Tb927.8.5060), which we showed previously
to be tagged with YnMyr in T. brucei using IP with an ARL6
speciﬁc antibody,17 was a signiﬁcant hit identiﬁed in both BSF
and PCF parasites.
In initial analyses using AzTB as capture reagent, no YnMyr-
modiﬁed peptides were identiﬁed; this is unsurprising because
the biotinylated peptide should remain partly anchored to the
resin and the large TAMRA-containing label hinders detection
by LC-MS/MS. We recently reported a series of related
reagents incorporating a trypsin cleavage site between the
TAMRA/biotin moieties and the azide capture group;25 these
reagents enabled identiﬁcation of YnMyr-tagged peptides in the
malaria parasite P. falciparum,10 human cancer cells,12 zebra-
ﬁsh,25 and Leishmania parasites.23 In the current study we used
AzRTB and AzRB (Supporting Information Figure S1), which
both incorporate an arginine trypsin cleavage site and biotin,
with AzRTB also featuring a TAMRA ﬂuorophore. Searches
were carried out with the additional mass fragment as a variable
modiﬁcation on any amino acid at a peptide N-terminus and
data ﬁltered to retain only those identiﬁcations meeting a
stringent score threshold, as established in our previous
studies25 (see Methods). Sixty-ﬁve identiﬁed modiﬁcation
Figure 4. Comparison of acylated proteins in two life stages of T. brucei. (a) Volcano plot comparing YnMyr intensities of hits (deﬁned as proteins
signiﬁcantly enriched over Myr controls in one or both life stages) by a two-sided two-sample permutation-corrected t test (250 permutations; FDR
0.01, s0 2). Those proteins identiﬁed in one life stage (BSF/PCF only) and N-terminal glycine-containing proteins (MG) are indicated. (b)
Comparison of relative abundance of protein hits in BSF and PCF parasites in the current study (LFQ quantiﬁcation; ratio of YnMyr intensities is
plotted) with the study of Butter et al. (quantiﬁcation via SILAC).39 Comparison with another previously reported data set is shown in Supporting
Information Figure S7. See also Supporting Information Table S4. (c) Heatmap and functional classiﬁcation of MG proteins found/enriched in one
of the two stages. YnMyr intensities shown and color-coded within each row. The total data set is shown in Supporting Information Figure S8.
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sites across BSF and PCF samples were matched to 56 discrete
proteins; peptides diﬀerently modiﬁed by methionine oxidation
or with diﬀerent lengths due to missed cleavages can derive
from the same protein sequence (Supporting Information
Table S3; see Supporting Information Figure S6 for examples
of assigned modiﬁed peptide spectra and Supporting
Information Data File for all spectra). Of these 65 peptides,
only 3 lacked an N-terminal glycine and corresponded to
proteins for which no other peptides were identiﬁed; therefore,
these are likely to be false-positive identiﬁcations. When
AzRTB was used to capture and enrich tagged proteins, 18
YnMyr-modiﬁed peptides (17 proteins) were detected in T.
brucei PCF samples. AzRB, however, resulted in more
identiﬁcations, with 30 modiﬁed N-terminal glycines detected
in PCF and 26 in BSF samples. Sixteen YnMyr modiﬁed N-
terminal glycines were detected independently with both
AzRTB and AzRB; these reagents result in remnants on the
modiﬁed peptide that are slightly diﬀerent in mass (by one
methylene unit), providing orthogonal evidence for modiﬁca-
tion of these peptides.
BSF and PCF parasites are adapted to very diﬀerent
environments, and the identiﬁcation of stage-speciﬁc proteins
expressed speciﬁcally in the insect vector or the host is an
ongoing area of research.39 Comparison of YnMyr LFQ
intensities of hits (deﬁned as proteins identiﬁed as signiﬁcantly
enriched over Myr controls in one or both life stages) by t test
revealed that a subset of non-MG and MG proteins were
diﬀerentially detected in one life stage over the other (Figure 4;
Supporting Information Table S4). The data are in good
agreement with existing studies. The ratio of BSF/PCF YnMyr
intensities for hits was plotted against the ratio from a
published data set where stable isotope labeling by amino acids
in cell culture (SILAC) quantitative proteomics was used to
compare the two life stages:39 pleasingly, for the 59 proteins
quantiﬁed by both studies (roughly half of the LFQ hits in our
comparison), the correlation was high (Pearson 0.87; Figure
4b). Our data are also in similarly good agreement with an
earlier SILAC-based study (Urbaniak et al.;40 Pearson
correlation 0.83; Supporting Information Figure S7). These
high correlations also show that, in most cases, YnMyr labeling
tracks protein abundance.
As expected, speciﬁc cell surface proteins such as GPI-PLC
and VSG were prominent in BSF samples, whereas MSP-B and
PSSA-2 were found in PCF samples, consistent with the large
changes that occur on the parasite’s surface coat. Functional
analysis of stage-enriched MG motif proteins revealed several
hits in the calpain family of cysteine peptidases, two protein
phosphatases with diﬀerent stage speciﬁcities, and proteins
involved in intracellular transport: phosphoinositide-speciﬁc
phospholipase C and receptor adenylate cyclase (GRESAG4)41
in PCF parasites and ARL1B enriched in BSF parasites (Figure
4c). Calpains are calcium-dependent cysteine peptidases, and T.
brucei possesses an expanded family of calpain-like proteins,
some of which have apparently no proteolytic activity but are
targeted by lipidation or other signals to diﬀerent subcellular
locations.42 Although the functions of these proteins are largely
unknown, they have been hypothesized to play regulatory roles,
for example, in cytoskeletal remodeling in the case of CAP5.5,18
or in virulence in the mammalian host in the case of MCA4.21
Given the widespread diﬀerential phosphorylation of BSF and
PCF T. brucei,43 the identiﬁed stage-enriched lipidated
phosphatases could also be particularly interesting for future
studies; for example, a recent analysis of two N-myristoylated
phosphatases demonstrated their importance at speciﬁc stages
of development in the malaria parasite.44 Thirteen MG proteins
currently of unknown function were also enriched in one of the
two stages. Interestingly, 12 lipidated proteins signiﬁcantly
enriched in our PCF data set were found to be up-regulated
early in diﬀerentiation from BSF to PCF parasites in a recent
proteomic study by Dejung et al.45 (Supporting Information
Figure 5. Comparison of myristate and palmitate tagging in T. brucei BSF. (a) BSF parasites were incubated with YnMyr or YnPal (Figure 2d)
probes for 8 h and tagged proteins visualized by in-gel ﬂuorescence after CuAAC. The gel was subject to treatment with NaOH and reimaged to
identify base labile bands. (b) Volcano plot comparing YnMyr and YnPal intensity for protein hits (signiﬁcantly enriched over Myr or Pal controls).
Two-sided two-sample permutation-corrected t test (250 permutations; FDR 0.05, s0 1). Proteins are categorized and color coded to indicate if they
were identiﬁed as palmitoylated by Emmer et al. (Tb PCF palmitoylome) or contain an N-terminal glycine (MG). “YnMyr only” indicates protein
not a hit in YnPal analyses. See also Supporting Information Figure S9 and Table S5.
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Figure S7). Other interesting hits are ARF protein ARLB and
calpain-like protein Tb927.1.2230, both enriched in our BSF
data and identiﬁed as transiently up-regulated during diﬀer-
entiation by Dejung et al., suggestive of roles in the
diﬀerentiation process. Overall, our data show that lipidated
proteins involved in carbohydrate metabolism, phosphorylation
processes, small-molecule, ion, and protein transport, and signal
transduction vary between BSF and PCF parasites (Supporting
Information Figure S8), consistent with the signiﬁcant changes
to cell structure and metabolism that accompany adaptation of
the cell to its diﬀerent host environments.
Proteomic Identiﬁcation of YnPal-Labeled Proteins in
T. brucei. As discussed above, GPI-anchored proteins and
glycoconjugates are prevalent in T. brucei, and these are known
to incorporate fatty acyl chains of various lengths. In addition,
fatty acids can be incorporated into proteins on cysteine side
chains; S-acylation with the 16-carbon fatty acid palmitate is a
common modiﬁcation across eukaryotes, including protozoan
parasites.46 In contrast to the high speciﬁcity of NMT for
myristoylation,6 S-acylation enzymes and pathways have been
shown to be promiscuous in accepting fatty acid analogues with
a variety of chain lengthsin mammalian cells at least.47 In an
additional layer of complexity, some proteins are dually
acylated, being N-myristoylated at the N-terminal glycine and
S-acylated with palmitate on a nearby cysteine residue.46
Furthermore, T. brucei is known to metabolize long-chain fatty
acids to meet its needs in diﬀerent life stages and culture
conditions,48 although whether alkyne-tagged analogues would
also be substrates for these metabolic enzymes is not known.
To provide additional insight into whether YnMyr was also
incorporated into S-palmitoylation sites and to establish a
broader picture of lipidation in T. brucei, longer chain palmitate
analogue YnPal (Figure 2d) was incubated with BSF parasites
at 100 μM for 4, 8, or 18 h, and samples were processed as
before. In-gel ﬂuorescence analysis revealed a distinct band
pattern for the two analogues (Figure 5a). Interestingly, in
contrast to YnMyr, YnPal was not visibly toxic to parasites, and
labeling intensity continued to increase slightly up to 18 h
(Supporting Information Figure S4). Similar to YnMyr, YnPal
was also incorporated into a base-sensitive band at ∼60 kDa,
although to a much lesser extent (Figure 5a). YnPal proteins
were enriched and analyzed by LC-MS/MS as described above,
and palmitic acid (Pal) controls were run in parallel. Results
were ﬁltered to retain only those in at least two of the three
replicates and data analyzed by LFQ (Supporting Information
Figure S9). This YnPal data set was compared to the YnMyr
BSF data set and also cross-compared with a data set of
potential palmitoylated proteins identiﬁed by Emmer et al.49 in
T. brucei PCF using acyl-biotin exchange chemistry (ABE)
(Supporting Information Table S5). ABE is an approach
complementary to click chemistry for palmitoyl-protein
discovery and identiﬁes proteins that bear hydroxylamine-labile
linkages at cysteine residues. Protein hits were then categorized
in the following way: (1) N-terminal glycine (MG) motif plus
detection in the experiments of Emmer et al.; (2) detection by
Emmer et al. but no MG motif; (3) MG proteins found in
YnMyr data sets only; (4) other MG motif proteins; (5) others
(Figure 5b). YnMyr and YnPal intensities of hits, deﬁned as
proteins signiﬁcant in one or both data sets and/or with direct
detection of the N-terminal YnMyr modiﬁed peptide, were
compared by t test (Figure 5b). A high degree of overlap was
observed between YnMyr and YnPal data sets: of 134 protein
hits, only 3 were exclusive to YnPal samples and 15 to YnMyr
samples. Most MG hits were identiﬁed either in YnMyr alone
(15 proteins) or in both data sets (32 proteins), whereas non-
MG hits also identiﬁed by Emmer et al. were mostly enriched
in YnPal samples compared to YnMyr, as expected (Figure 5b).
MG proteins detected as S-acylated by Emmer et al. also
identiﬁed in the current study include FCaBP, PPEF, and two
calpain-like proteins with homology to Leishmania small
myristoylated protein 1 (SMP-1), Tb927.1.2230, and
Tb927.1.2260; there is published evidence for the S-acylation
of these proteins on cysteines proximal to the N-terminal
myristoylation site.16,20,50 LFQ analyses also revealed enrich-
ment of known S-palmitoylated protein MCA4.21 Interestingly,
other members of this family (MCA3 and MCA1) were also
YnPal-enriched hits, suggesting that these interesting pseudo-
proteases may be S-acylated. Around 70 proteins lacking an
MG motif and identiﬁed as YnPal hits here were not found by
Emmer et al., likely due to stage-speciﬁc diﬀerences in the
proteome (insect stage PCF parasites in Emmer et al. and
human stage BSF cultures in the present study), and may also
reﬂect the complementarity of ABE and CuAAC-based
chemical proteomics for palmitoylated proteome analysis.
Proteins in the ARF/ARL family are not generally dually
acylated, and the large majority were indeed identiﬁed only in
YnMyr analyses. An interesting exception is the ARF protein
Tb927.9.13650 (and Tb927.9.13680, diﬀering by just one
amino acid), which was detected in YnPal analyses and contains
a cysteine strongly predicted to be palmitoylated (CSS-Palm;
Supporting Information Table S5).51 Consistent with gel-based
results (Figure 5a), the VSG was also enriched in YnPal
samples (Supporting Information Table S5), albeit to a lesser
extent than with YnMyr. Although previous data indicate that
myristate is speciﬁcally incorporated into the ﬁnal GPI anchor
of this protein, intermediates in the GPI anchor remodeling
process contain longer chain fatty acids, including potentially
stearate (C18:0).31,52 Alternatively, there are other examples of
variable lipid labeling in T. brucei, with evidence for
promiscuous incorporation and metabolism prior to incorpo-
ration of lipids. For example, the S-acylated protein
glycosylphosphatidylinositol-speciﬁc phospholipase C (GPI-
PLC), which is responsible for processing the GPI anchor of
VSG and other substrates, can be radiolabeled with myristate,
palmitate, or stearate;36 consistent with this, GPI-PLC was
detected with almost equal enrichment in our YnMyr and
YnPal analyses. In addition, labeling with either [3H]-myristate
or [3H]-palmitate results in both myristate and palmitate being
present on GPI-PLC, suggesting that trypanosomes can
interconvert these fatty acids. Indeed, at least in some culture
conditions, myristate is readily chain elongated in T. brucei to
palmitate and stearate.53 It is conceivable that YnMyr and
YnPal are processed by chain elongation/reduction by the
trypanosome fatty acid biosynthetic machinery and incorpo-
rated into the VSG and other proteins; because processing
occurs at the carboxyl end of the lipid, this would be expected
to conserve the alkyne tag. Further work will be required to
explore this possibility.
In summary, approximately 100 YnPal tagged targets have
been identiﬁed here, including both S-acylated and GPI-
anchored proteins.
Chemical Knockdown of NMT. NMT has been validated
preclinically as a drug target in T. brucei BSF via RNAi
knockdown and chemical inhibition of the enzyme, and target
engagement of inhibitor with NMT inside parasites was
demonstrated through the reduction of protein radiolabeling
ACS Infectious Diseases Article
DOI: 10.1021/acsinfecdis.6b00034
ACS Infect. Dis. XXXX, XXX, XXX−XXX
G
with [3H]-myristic acid following treatment with a T. brucei
NMT inhibitor (NMTi).7 Azido-myristate has also been used
to demonstrate that NMTi reduces tagging in the related
organism T. cruzi in a dose-dependent manner at the level of in-
gel ﬂuorescence,54 although tagged proteins were not identiﬁed.
Following a strategy similar to our recent studies in human
cells12 and L. donovani,23 we aimed to use quantitative
proteomics in combination with YnMyr and a TbNMT
inhibitor to provide orthogonal evidence for the identity of
NMT substrates while simultaneously deﬁning those substrates
that may mediate the phenotypes observed on inhibition.
TbNMT inhibitor 17 (Figure 6a) was co-incubated with
YnMyr in BSF parasites at concentrations ranging from 5 to
100 nM. A dose-dependent drop in labeling of most bands was
observed, with the notable exception of the VSG, consistent
with target engagement in the parasite (Figure 6b). Inhibitor 1
is reported to have an EC50 of 2 nM on BSF parasites and sub-
nanomolar IC50 against TbNMT and is eﬀective in eliminating
parasites in a mouse model of trypanosomiasis.7 A small panel
of analogues of 1,13a,55 with varying potency against TbNMT
(compounds 2−4, Figure 6a), was analyzed using YnMyr
tagging. In all cases the same trend toward decreased labeling
was observed, with the VSG band remaining largely unaﬀected
by NMT inhibition (Supporting Information Figure S10).
Following base treatment, quantiﬁcation of the decrease in
ﬂuorescence intensity suggested intracellular inhibition of N-
Figure 6. TbNMT inhibitors dose-dependently knock down YnMyr labeling. (a) Structures of previously reported TbNMT inhibitors 1−4, their
IC50 values against TbNMT, and tagging-IC50 (concentration of compound required for 50% inhibition of tagging, TC50) calculated based on
ﬂuorescent gels. (b) In-gel ﬂuorescence analysis of samples from parasites treated with indicated concentrations of 1 during YnMyr tagging. (c)
Quantiﬁcation of in-gel ﬂuorescence signal from NaOH-treated gels (n = 2−3) of samples from parasites co-incubated with inhibitors 1−4 and
YnMyr. See Supporting Information Figure S10 for example gels.
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myristoylation with a TC50 (concentration of compound
resulting in a 50% decrease in tagging) in the low nanomolar
range for 1, 3, and 4 and in the low micromolar range for 2, in
line with the measured enzyme potencies for these compounds
(Figure 6a,c). These data are consistent with the on-target
action of these inhibitors in parasites and provide further
evidence that the majority of base treatment-insensitive YnMyr
labeling in T. brucei BSF is NMT-dependent.
To identify proteins for which acylation levels were
selectively aﬀected by NMT inhibition, YnMyr-tagged BSF
parasites were treated with 1 at 5, 10, or 100 nM or with 2 at 1,
5, or 20 μM, concentrations designed to probe the range of
tagging reduction observed in gels for more and less potent
examples of TbNMT inhibitors. The resulting samples (16
total, including replicates) were subject to CuAAC, base
treatment to remove GPI-anchor tagging, enrichment, and LC-
MS/MS analysis; Myr controls were processed in parallel
(Supporting Information Figure S11). Data were analyzed by
MaxLFQ,34 and proteins quantiﬁed in both no-inhibitor
replicates were selected for analysis of enrichment levels over
background (YnMyr/Myr) and response to inhibitor (Support-
ing Information Table S6). A subset of MG proteins, including
almost all proteins identiﬁed as having a YnMyr-modiﬁed N-
terminus, were enriched over Myr controls, and this enrich-
ment reduced in response to the highest concentrations of
inhibitor (100 nM 1 and 20 μM 2) (Figure 7a). Examination of
enrichment ratios (enrichment over Myr controls, normalized
to samples with no inhibitor; see Methods for detailed
description of data processing and analysis) revealed 54
proteins that responded robustly to the highest concentrations
of both inhibitors 1 and 2. Of this subset, only one did not
contain an N-terminal glycine. Hierarchical clustering was
performed on the 54 putative hits, and 4 clusters of response
were deﬁned (Supporting Information Figure S12); protein
responses were further examined by plotting enrichment
relative to concentration of inhibitor (Table 1; Figure 7b;
Supporting Information Figure S13). The sole non-MG protein
(Tb927.8.2250, annotated as a putative tRNA ligase)
responded only to the highest concentration of NMT inhibitor
(Figure 7c) and may be a downstream or low-aﬃnity oﬀ-target
of the inhibitor. Interestingly, this protein was identiﬁed by
Emmer et al. as S-acylated in PCF parasites.49 The remaining
53 hits, classed as “high conﬁdence”, showed a variety of robust
dose−responses; a range of substrate sensitivity toward NMT
inhibition was also observed in human cells and Leishmania
parasites.12,23
In addition to the 53 high-conﬁdence hits, a further 10
proteins showed a weaker dose−response to NMT inhibitors,
but this group included 7 proteins in which the YnMyr-
modiﬁed peptide was identiﬁed on the N-terminal glycine. The
Figure 7. Chemical proteomic analysis of YnMyr tagging in the presence of NMT inhibitors. BSF parasites were labeled with YnMyr in the presence
of inhibitors 1 (5, 10, 100 nM) and 2 (1, 5, 20 μM). Proteins were subject to CuAAC, base treatment, enrichment, and on-bead digest in technical
duplicate and analyzed by LC-MS/MS with quantiﬁcation by LFQ. (a) Global data visualization after ﬁltering to retain only those proteins quantiﬁed
in both YnMyr replicates and imputation of missing values (see Methods for details). (Left) Response to 100 nM inhibitor 1 plotted against
enrichment over myristic acid (Myr) controls. (Right) Response to inhibitors 1 (100 nM) versus 2 (20 μM). Proteins containing an N-terminal
glycine (MG) and those for which the YnMyr-modiﬁed peptide was identiﬁed using reagent AzRB or AzRTB are indicated. (b) Dose−response plots
(treatment with 1) for protein hits. Curves are color-coded based on clustering (degree of response; see Supporting Information Figure S12). (c)
Dose−response plots (treatment with 1) for other MG proteins not assigned as hits (gray) and for outlier non-MG protein (Tb927.8.2250, black)
that decreases only at high concentrations of inhibitors. See also Supporting Information Table S6 and Figure S13 (dose−response curves for
treatment with 2 and for “medium conﬁdence” hits).
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10 proteins were thus assigned as “medium-conﬁdence” hits
and include FCaBP (previously identiﬁed as N-myristoylated)20
and putative N-myristoylated protein MCA4.21 The remaining
MG proteins, which neither responded in a dose-responsive
manner to NMT inhibitors nor had an identiﬁed N-terminal
modiﬁed glycine, were classed as nonsubstrates and included
Table 1. High- and Medium-Conﬁdence N-Myristoylated Protein Hitsa
aProteins were identiﬁed by quantitative proteomics with YnMyr in combination with NMT inhibitors. Mean normalized enrichment ratios
(YnMyr/Myr) are given, and cells are color-coded based on value (blue = 0, red = 1, yellow = 50 percentile). Proteins for which the YnMyr-modiﬁed
N-terminus was detected (Mod. Pept.) and those identiﬁed as hits in PCF samples are indicated. Some protein groups contained multiple proteins
(“&others”). See also Supporting Information Table S6.
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ribosomal proteins and others not expected to be myristoylated.
Notably, two widely used bioinformatics tools35,56 for
prediction of whether a protein is a likely NMT substrate
disagreed for 18 of the high-conﬁdence hits identiﬁed here and
predicted no myristoylation for an additional 7 (Supporting
Information Figure S14 and Table S7). This is not necessarily
surprising given that these tools were trained on data sets from
other organisms and highlights the value of experimentally
identifying NMT substrates.
Proteins for which the level of YnMyr tagging responded in a
dose-dependent manner to both NMT inhibitors are highly
likely to be NMT substrates (i.e., high-conﬁdence hits). These
included Golgi reassembly stacking protein (GRASP),
proteasome regulatory ATPase subunit 2 (RPT2), ﬁve
members of the ADP-ribosylation factor (ARF) family of
GTPases, four proteins involved in fatty acyl CoA synthesis,
four phosphatases (including PPEF), calpain-like proteins, and
many proteins of unknown function. Fifty percent of high-
conﬁdence NMT substrate proteins identiﬁed here are
associated with a loss of ﬁtness in RNAi knockdown
experiments in diﬀerent life stages or conditions (Supporting
Information Table S6; Alsford et al.;57 and data extracted from
TriTrypDB33) and merit further investigation as substrates with
the potential to mediate the antiparasitic eﬀects of TbNMT
inhibitors.
■ CONCLUSIONS
Here we have used chemical proteomics and a suite of chemical
toolsbioorthogonally tagged fatty acid analogues, CuAAC
capture reagents with cleavable moieties for myristoylation site
identiﬁcation, and N-myristoyltransferase inhibitorsto ex-
plore protein lipidation in the protozoan pathogen T. brucei.
We identify lipidated proteins in bloodstream and procyclic
form parasites and report the ﬁrst comparative quantitative
analysis of stage-enriched lipidated proteins. We also show that
alkyne palmitate analogue YnPal can be used to tag S-acylated
proteins in T. brucei; this analogue should prove a useful tool
for further exploring palmitoylacyltransferase enzymes as
potential drug targets. Furthermore, as we have previously
shown in other organisms,12,23 quantitative chemical proteo-
mics combined with well-characterized enzyme inhibitors
proved to be a powerful combination for clearly deﬁning
NMT substrates amid the complexity of metabolic tagging. The
N-myristoylated proteins identiﬁed here are involved in many
important cellular processes, and our data sets provide a rich
resource for future investigation of the complex and pleiotropic
impact of NMT inhibition in T. brucei. Data are available via
ProteomeXchange with identiﬁer PXD004053. Finally, tagging
of proteins by other mechanisms, for example, incorporation of
YnMyr into the GPI anchor of the VSG as shown here, suggests
that such analogues may also be useful tools for probing the
GPI anchor and lipid metabolism pathways in trypanosomes.
■ METHODS
Chemical Tools. The following chemical tools were
synthesized as described previously: YnMyr, YnPal, and
AzTB;58 AzMyr and YnTB;26 inhibitors 1 and 2;12 and AzRB
and AzRTB.25 Myristic and palmitic acids and all other
chemicals were purchased.
Parasite Culture. The T. brucei brucei BSF strain Lister 427
was maintained in vitro at 37 °C with 5% CO2 in HMI-9
medium containing 2 μg/mL geneticin (Invitrogen).59 The
Lister 427 strain is monomorphic and has lost the ability to
diﬀerentiate from long-slender trypomastigotes into the short-
stumpy form. Cells were routinely maintained at a density <1 ×
106/mL. The T. brucei brucei procyclic strain 449 was
maintained in vitro at 26 °C in SDM-79 medium containing
25 μg/mL phleomycin.59 Cells were routinely maintained at a
density <1.5 × 107/mL. All culture media contained 10%
tetracycline-free fetal bovine serum (Autogen Bioclear).
Metabolic Tagging Experiments. Parasites were meta-
bolically labeled by the addition of 100 μM myristic acid or
YnMyr to T. brucei BSF (set up at 2.5 × 105/mL in HMI-9
medium the previous day) or PCF (5 × 106/mL in SDM-79).
Cells were then grown for 8 h at 37 °C with 5% CO2 (BSF) or
for 18 h at 26 °C (PCF) before harvesting. Parasites were lysed
in ice-cold RIPA buﬀer (50 mM Tris, pH 7.4, 1% NP-40, 1%
sodium deoxycholate, 150 mM NaCl, 0.5% SDS, and 1×
Complete EDTA-free protease inhibitor cocktail (Roche)),
sonicated 3 × 10 s at amplitude 45 with 1 min intervals on ice,
and then centrifuged at 16000g for 30 min at 4 °C. For
inhibition experiments, parasites were pretreated for 1 h with
inhibitors 1−4 at indicated concentrations, and then Myr or
YnMyr probe was added for the remaining labeling time (8 h
for BSF, 18 h for PCF).
CuAAC Labeling, Pull-down, and Gel-Based Analysis.
CuAAC chemistry, pull-down, and gel-based analysis were
performed as described previously.23 In brief, proteins were
precipitated and resuspended, and CuAAC was performed as
described.26 Proteins were enriched on streptavidin or
neutravidin-coated beads. Visualization was carried out using
an Ettan DIGE Imager (Amersham Biosciences)-Cy3 channel
to detect TAMRA-labeled proteins.
Proteomic Sample Preparation and Analysis. Sample
preparation for proteomics analysis and LC-MS/MS was
carried out as described previously (also detailed in the
Supporting Information).12
Data Processing: General Comments. The data were
processed with MaxQuant version 1.5.3.8, and the peptides
were identiﬁed from the MS/MS spectra searched against the
TriTrypDB-25 T. brucei TREU927 database using the
Andromeda search engine. The VSG protein for the 427 strain
was not present in this database, and so initial experiments B1
and B2 (see below) were searched against the T. brucei Lister
strain 427. The TriTrypDB sequence for the identiﬁed VSG
variant Tb427.BES40.22 was appended to the TREU927
FASTA ﬁle. Cysteine carbamidomethylation was used as a
ﬁxed modiﬁcation, and methionine oxidation and N-terminal
acetylation were used as variable modiﬁcations. The false-
discovery rate was set to 0.01 for peptides, proteins, and sites.
Other parameters were used as preset in the software. “Unique
and razor peptides” mode was selected to allow for protein
grouping; this calculates ratios from unique and razor peptides
(razor peptides are uniquely assigned to protein groups and not
to individual proteins). LFQ experiments in MaxQuant were
performed using the built-in label-free quantiﬁcation algorithm
(MaxLFQ).34 Data were elaborated using Perseus version
1.5.0.31, Excel, and Graphpad Prism. The data have been
deposited to the ProteomeXchange with identiﬁer PXD004053.
Data Analysis. Enrichment LC-MS/MS experimental
design for YnMyr samples (for each experiment, both Myr
and YnMyr samples were processed; Table 2).
BSF Analysis. Data Set: Experiments B1−B4. For the
search, “match between runs” was enabled within parameter
groups but not between them (parameter groups: Myr,
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YnMyr). Replicates were grouped together (groups: Myr,
YnMyr). The YnMyr protein group was ﬁltered to require three
valid values across the four replicates and then ﬁltered to retain
only those proteins present in biological duplicate (present in
both experiments B1 and B2/3/4). Label-free intensities were
logarithmized (base 2), and empty values were imputed with
random numbers from a normal distribution, the mean and
standard deviation of which were chosen to simulate low-
abundance values close to noise level (impute criteria: width 0.1
and down shift 1.8; imputation for each sample individually). A
modiﬁed t test with permutation-based FDR statistics was
applied (250 permutations; FDR 0.001; s0 1) to compare Myr
and YnMyr groups.
PCF Analysis. Data Set: Experiments P1−P6. For the
search, “match between runs” was enabled within parameter
groups but not between them (parameter groups: Myr,
YnMyr). Replicates were grouped together (groups: Myr,
YnMyr). The YnMyr protein group was ﬁltered to require three
valid values across the four replicates and then ﬁltered to retain
only those proteins present in biological duplicate (present in
both experiments P1/3/6 and P2/4/5). Label-free intensities
were logarithmized (base 2) and empty values were imputed
with random numbers from a normal distribution (impute
criteria: width 0.1 and down shift 1.8; imputation for each
sample individually). A modiﬁed two-sample two-sided t test
with permutation-based FDR statistics was applied (250
permutations; FDR 0.001; s0 1) to compare Myr and YnMyr
groups.
BSF and PCF Comparisons. Data Set: Experiments B1−B4
and P1−P6. Data sets were searched together with MaxLFQ.
Data were ﬁltered for at least three valid values in at least one
group (groups: BSF_Myr, BSF_YnMyr, PCF_Myr, PCF_Yn-
Myr). The total data set was ﬁltered to require three
BSF_YnMyr or four PCF_YnMyr valid values and then
cross-referenced with individual analyses (described above) to
retain hits only. Missing values were imputed (impute criteria:
width 0.1 and down shift 1.8) and two-sample t tests used to
compare YnMyr intensities across BSF and PCF (250
permutations; FDR 0.01, s0 2). Data were elaborated in
Excel and compared to literature data sets.39,40,45
Modiﬁed Peptide Analyses. Data Sets: Experiments B4, P5,
and P6. MaxQuant searches were carried out as above with the
following modiﬁcations: the minimum peptide length was
reduced to 5. This is because the N-terminus of NMT
substrates often contains a lysine residue,35 resulting in short N-
terminal tryptic peptides. Modiﬁcation with YnMyr and the
expected portion of AzRB or AzRTB was speciﬁed as a variable
modiﬁcation. YnMyr-modiﬁed peptide matches were ﬁltered to
retain only those with a score (the Andromeda score for the
best identiﬁed among the MS/MS spectra) >40 and delta score
(the score diﬀerence to the second best peptide identiﬁcation)
>20.
YnPal and YnMyr Comparisons (BSF). Data Set: YnMyr
Experiments B2−B4. YnPal: Three Technical Repeats (A−C,
Processing from the Lysate Stage) of One Biological Sample
(YnPal and Pal Samples). Data were searched together by
MaxLFQ. Data were ﬁltered for at least two valid values in at
least one group (groups: Myr, YnMyr, Pal, YnPal). Label-free
intensities were logarithmized (base 2). YnMyr and YnPal data
sets were then analyzed separately: ﬁltered (at least two valid
values in either Myr or YnMyr; at least two valid values in
either Pal or YnPal), missing values were imputed (impute
criteria: width 0.1 and down shift 1.8) and two-sample t tests
used to deﬁne potential hits in each case (250 permutations;
FDR 0.05, s0 1). The total data set was then cross-referenced
with individual analyses to retain hits only (t test signiﬁcant
proteins and those where modiﬁed peptide was identiﬁed).
Missing values were imputed (impute criteria: width 0.1 and
down shift 1.8, across total data set) and two-sample t tests
used to compare YnMyr and YnPal intensities (250
permutations; FDR 0.05, s0 1). Data were elaborated in
Excel and compared to a literature data set.49
YnMyr Tagging in the Presence of NMT Inhibitors (BSF).
Groups (Conditions): YnMyr, Myr, 5 nM 1, 10 nM 1, 100 nM
1, 1 μM 2, 5 μM 2, and 20 μM 2. . All samples were prepared
and processed in duplicate (technical replicates A and B from
the lysate stage). The “match between runs” option (time
window 0.7 min, alignment time window 20 min) in MaxQuant
was enabled during the searches. LFQ data were grouped and
ﬁltered to retain only those proteins present in both YnMyr
replicates. The mean of the technical replicates was calculated,
and then missing values were imputed from a normal
distribution (width 0.1, downshift 1.8; separately for each
data set). Response ratios (YnMyr/(YnMyr + inhibitor)) and
enrichment ratios ((YnMyr + inhibitor)/Myr) were calculated,
and enrichment ratios were subsequently normalized to YnMyr
only (no inhibitor) to compare between proteins and across
conditions. Proteins with −Log2((YnMyr + inhibitor)/Myr) >
2 (response ratio > 2) for 100 nM 1 and 20 μM 2 were selected
as potential hits. These hits were further analyzed by plotting
the dose−response curves (normalized enrichment ratios).
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